Multiple Cutaneous Squamous Cell Carcinoma in Immunosuppressed vs Immunocompetent Patients

Abstract

Discussion | Patients with HS have malignant lymphomas more frequently than the general population. Rates of NHL, HL, and CTCL in the general population are low. However, patients with HS appear to have 2 to 4 times the overall risk of developing lymphomas.Overall and subgroup associations between HS and lymphoma subtypes have not been evaluated previously in a population. A single-center retrospective series identified 1776 patients with HS in whom frequency of unspecified lymphoma was 1.8%. 5 In a Swedish retrospective analysis including 2119 patients hospitalized for HS, 6 cases of any hematopoietic cancer, which may include lymphomas, were identified. 6 Neither study observed greater risk of malignant lymphoproliferative disease among patients with HS.A limitation of our study was that we could not assess the disease duration or severity in this claims analysis. The uncommonness of the event did not permit us to evaluate systemic treatment or other exposures and the association between HS and lymphoma. To our knowledge, this is the first investigation to systematically evaluate this association in a US population of patients with HS. Size and diversity of our cohort may overcome selection biases and limitations inherent to smaller cohorts recruited with specialty centers.

Comprehensive Analysis of Myeloid Signature Genes in Head and Neck Squamous Cell Carcinoma to Predict the Prognosis and Immune Infiltration

“…The heterogeneity of HNSCC in part is derived from molecular changes of the parenchyma ( 1 ), but also from the intricate and versatile tumor microenvironment ( 14 , 15 ). In squamous cell carcinomas, the incidence is lower in immunocompetent patients ( 16 ), and low immune infiltration has been shown to associate with a poor prognosis ( 17 ). Noteworthy, cancer patients with prospering immune responses are more likely to benefit from immune therapy ( 18 ).…”

Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade

“…Fitting with the well-established observation that the incidence of squamous cell carcinomas is higher in immunocompromised patients (Herman et al 2007;Gonzalez et al 2019), the alleviation of cancer-potentiated immune suppression has shown potential in reducing HNSCC tumor burden and improving patient quality of life (Ferris et al 2016;Ferris et al 2018;Cohen et al 2019). The success of monoclonal antibodies blocking immune checkpoint receptor (ICR) signaling has transformed the landscape of emerging cancer therapeutic pipelines.…”

Skin cancer multiplicity in lung transplant recipients: a prospective population‐based study

“…Besides signifying the sheer tumour burden in affected lung transplant recipients, multiple skin cancers have prognostic significance, as immunosuppressed patients with multiple SCCs appear to have poorer outcomes than those with single tumours. 12 It is therefore clinically important to address these gaps in knowledge about multiple skin cancers in transplant recipients. In a population-based cohort of lung transplant recipients, we estimated the age-standardized incidence rates of SCC and BCC in terms of persons affected and multiplicity of tumours, and we examined the associations between potential risk factors and multiple SCCs and BCCs.…”

“…Besides signifying the sheer tumour burden in affected lung transplant recipients, multiple skin cancers have prognostic significance, as immunosuppressed patients with multiple SCCs appear to have poorer outcomes than those with single tumours . It is therefore clinically important to address these gaps in knowledge about multiple skin cancers in transplant recipients.…”